Autopsy report · NCT04821271

Antidepressant Effects of TS-161 in Treatment-Resistant Depression

“due to low recruitment”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 months before it started.
• Ran for about 2 years 11 months before it stopped.
• 11 participants enrolled.
• Results were posted on the registry 1 year 1 month after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

National Institute of Mental Health (NIMH)

Sponsor type

US National Institutes of Health

Conditions

Major Depressive Disorder; Treatment-Resistant Depression; Depression

Interventions

Placebo; TS-161

Participants

11

Sites

1

Countries

United States

Trials that died the same way

• Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements
  “Due to Poor Recruitment” (95% match in meaning)
• REALIB-LLA-2017: Idelalisib in Patients With Acute Lymphoblastic Leukemia
  “Because of low recruitment” (94% match in meaning)
• BicepsTenodesis vs. Biceps Debridement in Combined RC Tears and SLAP Lesions
  “Due to low recruitment rate” (93% match in meaning)
• Seropositivity and Adverse Birth Events in Migrants From Bilharzia-endemic Areas
  “due to lack of recruitment” (92% match in meaning)
• Robotic Therapy and Transcranial Direct Current Stimulation in Patients With Stroke
  “Because of low recruitment rates” (89% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.